For: | Alamoudi JA, Li W, Gautam N, Olivera M, Meza J, Mukherjee S, Alnouti Y. Bile acid indices as biomarkers for liver diseases I: Diagnostic markers. World J Hepatol 2021; 13(4): 433-455 [PMID: PMC8080550 DOI: 10.4254/wjh.v13.i4.433] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v13/i4/433.htm |
Number | Citing Articles |
1 |
Matthias Grimmler, Tobias Frömel, Angelique Masetto, Holger Müller, Tina Leber, Christoph Peter. Performance evaluation of enzymatic total bile acid (TBA) routine assays: systematic comparison of five fifth-generation TBA cycling methods and their individual bile acid recovery from HPLC-MS/MS reference. Clinical Chemistry and Laboratory Medicine (CCLM) 2024; doi: 10.1515/cclm-2024-1029
|
2 |
J. Jose Corbalan, Pranavi Jagadeesan, Karla K. Frietze, Rulaiha Taylor, Grace L. Gao, Grant Gallagher, Joseph T. Nickels. Humanized monoacylglycerol acyltransferase 2 mice develop metabolic dysfunction-associated steatohepatitis. Journal of Lipid Research 2024; 65(12): 100695 doi: 10.1016/j.jlr.2024.100695
|
3 |
Sayed Obaidullah Aseem, Phillip B. Hylemon, Huiping Zhou. Bile Acids and Biliary Fibrosis. Cells 2023; 12(5): 792 doi: 10.3390/cells12050792
|
4 |
Rulaiha Taylor, Veronia Basaly, Bo Kong, Ill Yang, Anita M Brinker, Gina Capece, Anisha Bhattacharya, Zakiyah R Henry, Katherine Otersen, Zhenning Yang, Vik Meadows, Stephanie Mera, Laurie B Joseph, Peihong Zhou, Lauren M Aleksunes, Troy Roepke, Brian Buckley, Grace L Guo. Effects of therapeutically approved individual bile acids on the development of metabolic dysfunction-associated steatohepatitis a low bile acid mouse model. Toxicological Sciences 2024; 202(2): 179 doi: 10.1093/toxsci/kfae110
|
5 |
Wenkuan Li, Jawaher Abdullah Alamoudi, Nagsen Gautam, Devendra Kumar, Macro Olivera, Yeongjin Gwon, Sandeep Mukgerjee, Yazen Alnouti, Amal Santra. Urinary BA Indices as Prognostic Biomarkers for Complications Associated with Liver Diseases. International Journal of Hepatology 2022; 2022: 1 doi: 10.1155/2022/5473752
|
6 |
Harry Sutton, Ronald J. Sokol, Binita M. Kamath. IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?. Hepatology 2024; doi: 10.1097/HEP.0000000000001032
|
7 |
Jie Li, Xiaolong Lian, Baojian Li, Quhuan Ma, Lingling Yang, Guangmiao Gao, Tingmei Yin, Xiaoyan Fu, Yi Deng, Zhijun Yang, Xiujuan Yang. Pharmacodynamic material basis of licorice and mechanisms of modulating bile acid metabolism and gut microbiota in cisplatin-induced liver injury based on LC-MS and network pharmacology analysis. Journal of Ethnopharmacology 2025; 340: 119293 doi: 10.1016/j.jep.2024.119293
|
8 |
A Current Understanding of Bile Acids in Chronic Liver Disease. Journal of Clinical and Experimental Hepatology 2022; 12(1): 155 doi: 10.1016/j.jceh.2021.08.017
|
9 |
Leon Deutsch, Alexandros Sotiridis, Boštjan Murovec, Janez Plavec, Igor Mekjavic, Tadej Debevec, Blaž Stres. Exercise and Interorgan Communication: Short-Term Exercise Training Blunts Differences in Consecutive Daily Urine 1H-NMR Metabolomic Signatures between Physically Active and Inactive Individuals. Metabolites 2022; 12(6): 473 doi: 10.3390/metabo12060473
|
10 |
Bandar D. Alrehaili. Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders. Saudi Journal of Gastroenterology 2024; 30(5): 283 doi: 10.4103/sjg.sjg_53_24
|
11 |
Rulaiha Taylor, Zhenning Yang, Zakiyah Henry, Gina Capece, Vik Meadows, Katherine Otersen, Veronia Basaly, Anisha Bhattacharya, Stephanie Mera, Peihong Zhou, Laurie Joseph, Ill Yang, Anita Brinker, Brian Buckley, Bo Kong, Grace L Guo. Characterization of individual bile acids in vivo utilizing a novel low bile acid mouse model. Toxicological Sciences 2024; 199(2): 316 doi: 10.1093/toxsci/kfae029
|
12 |
Gopanandan Parthasarathy, Harmeet Malhi, Jasmohan S. Bajaj. Therapeutic manipulation of the microbiome in liver disease. Hepatology 2024; doi: 10.1097/HEP.0000000000000987
|